SEC filing record
Primary Source · SEC.gov

801 West Biotech Opportunity Series 1

Fund Vehicle2026 vintageRule 506(b), Section 3(c), Section 3(c)(7)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalNew Form D filerForm D · 2026-08-13Last filing 2026-08-13

Raised

$57M

Investors

27

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

801 West Biotech Opportunity Series 1 is a Delaware entity that filed a Form D with the SEC on August 13, 2026, describing itself as a hedge fund. The offering claims Rule 506(b), Section 3(c), Section 3(c)(7) and covers pooled investment fund interests. 801 West Biotech Opportunity Series 1 reported $56,885,000 sold from 27 investors in an offering of indefinite size as of the Form D filed August 13, 2026. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. The issuer's address of record is 310 N State Street, Suite 220, Lake Oswego, OR 97034.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0002081340
Entity Name801 West Biotech Opportunity Series 1
ExemptionRule 506(b), Section 3(c), Section 3(c)(7)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising. Section 3(c) of the Investment Company Act of 1940: the issuer is a pooled investment vehicle relying on an exclusion from registration as an investment company. Section 3(c)(7) of the Investment Company Act: the fund is excluded from investment-company registration because every investor is a qualified purchaser, generally an individual with at least $5 million in investments or an institution with at least $25 million.
Entity TypeOther
Jurisdiction of OrganizationDelaware
Issuer Address310 N State Street, Suite 220, Lake Oswego, OR 97034
Phone(503) 548-1730
Industry / Fund TypePooled Investment Fund · Hedge Fund
Investment Company ActExcluded under Section 3(c)(7) (qualified purchasers only)
Securities TypePooled investment fund interests
First Sale DateAugust 1, 2025
Filing DateAugust 13, 2026
Accession Number0001104659-26-095672
Total Offering AmountIndefinite
Total Amount Sold$56,885,000
Total Investors27
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationIntended to last more than one year
Net Asset Value RangeDecline to Disclose
State (Issuer Address)OR
Amendment Count2 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

2

latest Aug 13, 2026

Critical / warning

0 / 0

1 watch · 1 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

2

raising

Latest event New filer · Aug 13, 2026

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 2 filing events with values and deltas, latest 2026-08-13, and alerts on the next one
  • 2 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Adviser of Record (Form ADV)

801 West Capital Management, LLC

CRD 168417 · SEC-registered adviser · lists this fund on Schedule D 7.B.(1) as a hedge fund

Auditor named on Form ADV: Rsm LLP · PCAOB-registered per the adviser

From the adviser's Form ADV as loaded from the SEC bulk data, joined on this issuer's Form D file number. Fund-level figures and the adviser's full fund roster are in the terminal.

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

801 West Capital Management, LLC

Executive Officer · Lake Oswego, OR

General Partner of the Issuer

Jonathan McGowan

Executive Officer · Lake Oswego, OR

Executive officer of 801 West Capital Management, LLC, General Partner of the Issuer

Scott Kelly

Executive Officer · Lake Oswego, OR

Executive officer of 801 West Capital Management, LLC, General Partner of the Issuer

Corey Von Allmen

Executive Officer · Lake Oswego, OR

Executive officer of 801 West Capital Management, LLC, General Partner of the Issuer

Questions About 801 West Biotech Opportunity Series 1

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is 801 West Biotech Opportunity Series 1?

801 West Biotech Opportunity Series 1 is a Delaware entity that filed a Form D with the SEC on August 13, 2026 as a hedge fund. The filing claims Rule 506(b), Section 3(c), Section 3(c)(7) for an offering of pooled investment fund interests.

Is 801 West Biotech Opportunity Series 1 legit?

AltStreet does not rate legitimacy; it reports the public record. 801 West Biotech Opportunity Series 1 filed a Form D with the SEC on August 13, 2026 claiming Rule 506(b), Section 3(c), Section 3(c)(7). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $56,885,000 sold to 27 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is 801 West Biotech Opportunity Series 1 registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that 801 West Biotech Opportunity Series 1 claimed Rule 506(b), Section 3(c), Section 3(c)(7) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has 801 West Biotech Opportunity Series 1 raised?

801 West Biotech Opportunity Series 1 reported $56,885,000 sold from 27 investors in an offering of indefinite size as of the Form D filed August 13, 2026.

Who can invest in 801 West Biotech Opportunity Series 1?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. Because the fund also relies on Section 3(c)(7), each investor must be a qualified purchaser, generally an individual with at least $5 million in investments. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in 801 West Biotech Opportunity Series 1?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling 801 West Biotech Opportunity Series 1 and how are they paid?

The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly.

Who is behind 801 West Biotech Opportunity Series 1?

The Form D lists 4 related persons: 801 West Capital Management, LLC, executive officer (General Partner of the Issuer); Jonathan McGowan, executive officer (Executive officer of 801 West Capital Management, LLC, General Partner of the Issuer); Scott Kelly, executive officer (Executive officer of 801 West Capital Management, LLC, General Partner of the Issuer); Corey Von Allmen, executive officer (Executive officer of 801 West Capital Management, LLC, General Partner of the Issuer). Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is 801 West Biotech Opportunity Series 1 located?

The issuer's address on its SEC filings is 310 N State Street, Suite 220, Lake Oswego, OR 97034. Its phone number of record is (503) 548-1730. It is organized under the laws of Delaware.

How long is the 801 West Biotech Opportunity Series 1 offering open?

The issuer indicated that the offering is intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.

How large is 801 West Biotech Opportunity Series 1?

The issuer declined to disclose its net asset value range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.